SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
TCRX

TScan Therapeutics, Inc. (NASDAQ:TCRX)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.15+$0.00 (+2.24%)
 
Market cap
$9.27M
Insider Score
Health Score
Analyst consensus
Listed since
Jul 16, 2021
Website
Market Cap$9.27M-85.3%
Revenue (ttm)$5.19M-38.4%
Net Income-$115.09M+19.3%
EPS-$0.88+21.4%
Shares Out63.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume391,711
Open$0.14
Previous Close$0.14
Day's Range$0.14 - $0.15
52-Week Range$0.14 - $1.47
Beta1.19
AnalystsBuy
Price Target$1.00(+585.40%)
Earnings DateMar 3, 2027

About TCRX

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Address
830 Winter Street, Waltham, MA, 02451, US
Market Cap
9 million
Employees
138
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$145.53K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Hold
0 Buy3 Hold0 SellAvg target $1.00 (+585.4%)

3 firms rating TCRX in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From TCRX’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
+2.24%
5 Days
-9.15%
1 Month
-32.52%
6 Months
-86.24%
1 Year
-85.27%

$TCRX stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in TCRX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by TCRX's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

TCRX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

TCRX Revenue by Segment

$16.52MTotal
Laboratory supplies, research materials and studies$6.00M36.32%
Clinical studies$4.61M27.89%
Legal and professional fees$1.95M11.78%
Facility-related and other$1.58M9.58%
Stock-based compensation$1.08M6.52%
Interest and other income, net$721.00K4.36%
Collaboration and license revenue$586.00K3.55%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New TCRX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to TCRX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in TCRX

VTIVanguard Morningstar Total Stock Market ETF$253.45K
VXFVanguard Extended Market ETF$116.17K
IWCiShares Micro-Cap ETF$22.03K
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF$10.00K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from TCRX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
3
Sells
0
Buy Value
$145.53K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.01%

Weight is the stock’s share of each fund’s holdings.